Baupost Group dumps Akebia Therapeutics, Inc.



© Reuters. Baupost Group dumps Akebia Therapeutics, Inc.

On the 30th of September, the Baupost Group sold all their 18 million Akebia Therapeutics, Inc. (NASDAQ:) shares for $44 million at an average price of $2.51 per share.
Shares of Akebia Therapeutics, Inc. are up 17.53% since the transaction.

The Baupost Group’s holding in Akebia Therapeutics, Inc. were completely closed with the transaction.

The Baupost Group first bought Akebia Therapeutics, Inc. stock in the fourth quarter of 2018.
The Baupost Group also owns Theravance Biopharma, Inc. (NASDAQ:).
Akebia Therapeutics, Inc. was its pre-sell number two position by number of shares and market value among pharmaceuticals stocks.

Other investors who also sold all their Akebia Therapeutics, Inc. shares include Millennium Management.
Contrary to the Baupost Group, California State Teachers Retirement System, the T. Rowe Price Equity Income Fund, and Victory Capital Management added to AKBA shares.

The Baupost Group also added to their share in Viasat, Inc. (VSAT) and Translate Bio, Inc. (NASDAQ:).
The total value of the shares bought is estimated at around $103 million.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link